Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study
| Autor: | Freddy Sitas, Sam Egger, Ian H. Frazer, Rohit Sinha, Louiza S. Velentzis, Dianne L. O'Connell, Emily Banks, Karen Canfell, Jessica Darlington-Brown |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Adult
medicine.medical_specialty Genotype HPV 16 HPV18 Population Etiology - Endogenous Factors in the Origin and Cause of Cancer Uterine Cervical Neoplasms Seroprevalence Antibodies Viral Cervical intraepithelial neoplasia Serology Age Medical microbiology Seroepidemiologic Studies Humans Medicine education Genotyping Gynecology Human papillomavirus 16 education.field_of_study Chlamydia Human papillomavirus 18 High grade cervical dysplasia business.industry Obstetrics Papillomavirus Infections Vaccination Australia Middle Aged Uterine Cervical Dysplasia medicine.disease female genital diseases and pregnancy complications Infectious Diseases Female Squamous Intraepithelial Lesions of the Cervix New South Wales business Research Article Cancer Type - Cervical Cancer |
| Zdroj: | BMC Infectious Diseases |
| ISSN: | 1471-2334 |
| DOI: | 10.1186/s12879-014-0676-z |
| Popis: | Background Australia commenced human papillomavirus (HPV) vaccination in 2007, with a two-year catch-up to the age of 26; catch-up cohorts are thus now entering their thirties. Plans for monitoring vaccine impact involve pre- and post-vaccination assessment of cervical HPV DNA in the general population and in high grade abnormalities. Although HPV serology is less sensitive than DNA genotyping, it assesses lifetime exposure and may be easier to measure in the general population. However, benchmark pre-vaccination seroprevalence of vaccine-included types in unvaccinated women with high grade abnormalities has not previously been reported. Methods We assessed seroprevalence for HPV16/18 from a population-based sample of 3,729 women with normal cytology and 971 women with confirmed high grade abnormalities (CIN2/3), aged 30–64 years, unvaccinated, and recruited in New South Wales in 2006–2010. We examined the variation in HPV16/18 seropositivity by age and in relation to a range of reproductive and behavioural characteristics in the subgroup of normal cytology women with no recent history of high grade cervical disease. Results The HPV 16, 18 and combined seroprevalence was 19%, 7% and 24% among women with normal cytology, and 39%, 13% and 44% among women with CIN2/3, respectively. For both groups, HPV16/18 seroprevalence was highest at age 30–39 years and decreased with age. In multivariable analysis for women with normal cytology, HPV16 and HPV18 seropositivity were each associated with the number of lifetime sexual partners (p-trend |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|